Corcept Therapeutics logo

Corcept Therapeutics

CORT | NASDAQ
Chart Builder DCF Calculator
$69.22
-$3.72 (-5.10%)
At close: Nov 16, 2026, 4:00 PM ET
$70.57
+$1.35 (+1.95%)
After-hours: Nov 16, 2026, 7:54 PM ET
-5.10%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
73.2
Fundamentals Excellent
Market Sentiment Neutral
Moat Narrow
Sector Rank #37/1021 (Top 4%)

Key Statistics

Market Data

Market Cap $7.58B
1D Range
68.63 72.62
52W Range
32.15 123.57

Valuation (TTM)

PE 54.50
PB 9.09
EV/EBITDA 56.45

Valuation (NTM)

Forward PE 32.27
Forward PEG 0.36
Price Target $150.00
Loading financial charts...

Profile

Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments fo...

Sector Healthcare
Employees 730
IPO Date Apr 14, 2004
Fiscal Year January - December

Latest News

ESMO Rare Cancers Publishes Case Report Detailing Eight-Year Response to Relacorilant Plus Nab-Paclitaxel in Metastatic Vulvar Cancer

16 hours ago · gurufocus.com

ESMO Rare Cancers Publishes Case Report Detailing Eight-Year Response to Relacorilant Plus Nab-Paclitaxel in Metastatic Vulvar Cancer
CORT's Q3 Earnings Beat, Higher Product Sales Aid Y/Y Revenues

13 days ago · zacks.com

CORT's Q3 Earnings Beat, Higher Product Sales Aid Y/Y Revenues
Corcept Therapeutics Incorporated (CORT) Q3 2026 Earnings Call Transcript

13 days ago · seekingalpha.com

Corcept Therapeutics Incorporated (CORT) Q3 2026 Earnings Call Transcript
Corcept Therapeutics Q3 Earnings Call Highlights

13 days ago · marketbeat.com

Corcept Therapeutics Q3 Earnings Call Highlights
Corcept Therapeutics (CORT) Q3 Earnings and Revenues Surpass Estimates

13 days ago · zacks.com

Corcept Therapeutics (CORT) Q3 Earnings and Revenues Surpass Estimates
Can Lifyorli Aid Corcept's Long-Term Growth Prospects Beyond Korlym?

29 days ago · zacks.com

Can Lifyorli Aid Corcept's Long-Term Growth Prospects Beyond Korlym?
Corcept Announces Planned Leadership Transition

2 months ago · businesswire.com

Corcept Announces Planned Leadership Transition

2 months ago · zacks.com

CHMP Backs CORT's Lifyorli Combo in Platinum-Resistant Ovarian Cancer
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)

2 months ago · businesswire.com

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)
Will Korlym Continue to Aid CORT's Growth Through the Rest of 2026?

2 months ago · zacks.com

Will Korlym Continue to Aid CORT's Growth Through the Rest of 2026?

Earnings

Latest Earnings
Nov 3, 2026
EPS
$1.01
Beat +20.24%
REV
$340.47M
Beat +0.40%
Next Earnings
Feb 23, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
5
Consensus
Buy
Price Target
$150.00
Upside
+116.70%
Buy (4)
Hold (0)
Sell (1)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.